GlobeNewswire

Cornell receives $35M to support cassava development for smallholder farmers in sub-Saharan Africa

Dela

Ithaca, New York, Feb. 15, 2018 (GLOBE NEWSWIRE) -- Cassava is vital to the food security of millions of Africans who eat some form of the root crop daily. Although cassava breeders are making progress, they still face significant challenges in developing disease-resistant varieties that also increase overall yield and respond to the needs of smallholder farmers and processors. Cornell University will expand international efforts to deliver improved varieties of cassava to smallholder farmers in sub-Saharan Africa with $35 million in new funding from the Bill & Melinda Gates Foundation and UK aid from the United Kingdom.

"This grant funds a second five-year phase that will allow us to build on previous work and focus on getting improved varieties into farmers' fields," said Ronnie Coffman, international plant breeder and director of Cornell's International Programs in the College of Agriculture and Life Sciences, who leads the project. 

During Phase 1 of the Next Generation Cassava Breeding project - also funded by the Gates Foundation and UK aid from 2012 to 2017 - researchers shortened the breeding cycle for new cassava varieties by improving flowering and using genomic selection. Through analyzing plant genotypes and identifying cassava lines with desirable traits, such as resistance to cassava brown streak disease or high dry matter content, breeders also improved their ability to make selections based on genetics and probability without having to wait for seedlings to reach adulthood. These methods save breeding time for a crop where flowering and sexual propagation are issues.

Another goal of Phase 1 was to make cassava genomic information publicly accessible on an open database. Cassava researchers all over the world are now comparing results and improving breeding programs without duplicating efforts by using Cassavabase. To reduce cost per progeny and improve the quality of data uploaded to Cassavabase in Phase 2, NextGen researchers will use additional methods of whole genome sequencing. 

"Our focus for the next five years will be to translate this research into breeding practices to increase impact," said Chiedozie Egesi, NextGen project director and adjunct professor of plant breeding and genetics at Cornell, who is based at the International Institute of Tropical Agriculture (IITA) in Nigeria. "A key goal in Phase 2 will be to identify traits preferred by farmers and end-users and incorporate them into new cassava lines to ensure that varieties are responsive to people's needs."

Egesi said, "We believe we will accelerate genetic gain as well as adopted genetic gain, increase the yields and resilience of cassava production by smallholder farmers, and move African cassava breeding toward greater capacity."

"Among the 30 new clones developed at IITA using our methods, 10 had higher dry matter yield than any clone currently available for smallholder farmers in Nigeria," said Jean-Luc Jannink, a research plant geneticist with the United States Department of Agriculture, Agricultural Research Service  (USDA-ARS) and Cornell adjunct associate professor in the Department of Plant Breeding and Genetics at Cornell. "Dry matter yield is a close proxy to food yield. Conservatively, we believe that we will increase the rate of genetic gain in cassava by 30 to 50 percent." 

Said Peter Kulakow, IITA cassava breeder and geneticist: "Genetic gain is a measure of the improvement of plant performance between generations and a goal of most modern breeding programs. Swifter improvements mean more new varieties can be tested and released." 

At the sixth annual Next Gen Cassava meeting, Feb. 19-24 in Dar es Salaam, Tanzania, teams of NextGen breeders, geneticists, data analysts, computer programmers, food technologists, social scientists and crop protectionists will be focusing on goals for Phase 2 and discussing how to better coordinate and leverage the exchange of germplasm and genotypic and phenotypic data from each other.

Developing capacity for sustainable breeding programs

Compared with other major staples like maize, rice and wheat, cassava has undergone few advances in productivity and yield over the last 50 years, making it an ideal candidate for breeding improvement. Because cassava is clonally propagated and has a low multiplication rate, it can take almost six to eight years before a new cassava variety makes it from breeders' nurseries through field trials to farmers' fields. Most breeding efforts focus on product development  - goals set by scientists and researchers without accounting for the preferences of farmers. In practice, this can result in poor adoption of new varieties and unrealized potential. 

"Breeders must be able to more quickly develop cassava varieties that resist diseases, are climate resilient and meet the needs of end-users and consumers," said Egesi.

Strengthening the capacity of national breeding programs will be critical in achieving self-sustaining breeding systems in sub-Saharan Africa. Over the next five years, NextGen researchers will continue to train the next generation of sub-Sahara African cassava breeders in modern plant breeding techniques like genomic selection and improved breeding methods.

International and regional partnerships are another important element of sustainability. NextGen researchers are reaching out to their counterparts in Ghana, Rwanda, Mozambique, Sierra Leone and the Democratic Republic of Congo to create a broader network of researchers who can work together to improve livelihoods and food security.

In Africa, NextGen collaborators include the International Institute of Tropical Agriculture, the National Root Crops Research Institute and West Africa Centre for Crop Improvement in Nigeria; the National Crops Resources Research Institute and Makerere University in Uganda; and the Tanzania Agricultural Research Institute in Tanzania. In South America, collaborators include Embrapa in Brazil and the International Center for Tropical Agriculture in Colombia. In the US, collaborators are Cornell University (who leads the project), the Boyce Thompson Institute at Cornell, the University of Hawaii, and the USDA-ARS in Ithaca.

For more information see www.nextgencassava.org   

 

 

# # #

Attachments:

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/d1896398-975a-4943-85b0-4f4b165f5678

Attachments:

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/4e3e5f6e-d4b9-45d1-b74d-8248eb7bb1ba

Linda McCandless
Cornell University 
6072275920
llm3@cornell.edu



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Cornell University via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Modus Therapeutics has successfully dosed first cohort in phase 1 study of subcutaneously administered sevuparin22.2.2019 08:00:00Pressmeddelande

STOCKHOLM, February 22, 2019. Karolinska Development's portfolio company Modus Therapeutics announces today that the first cohort has been successfully dosed in its phase 1 study to explore the pharmacokinetics, safety and tolerability of subcutaneous sevuparin injections in healthy adults. Modus Therapeutic develops sevuparin for diseases with high unmet medical need with a focus on sickle cell disease (SCD) - a painful, inherited blood disorder affecting millions of people around the globe. Sevuparin has the potential to improve the SCD patients' blood flow reducing their pain and the amount of time they will need to spend in hospital. Intravenously administered sevuparin is currently being tested in a phase 2 study which completed enrollment in January 2019 and will report data in mid-2019. In order to broaden sevuparins potential to help SCD patients outside of the hospital setting, Modus Therapeutics in parallel explores subcutaneously administered sevuparin. The first cohort in a

Karolinska Development's portfolio company Modus Therapeutics has successfully dosed first cohort in phase 1 study of subcutaneously administered sevuparin22.2.2019 08:00:00Pressmeddelande

STOCKHOLM, February 22, 2019. Karolinska Development's portfolio company Modus Therapeutics announces today that the first cohort has been successfully dosed in its phase 1 study to explore the pharmacokinetics, safety and tolerability of subcutaneous sevuparin injections in healthy adults. Modus Therapeutic develops sevuparin for diseases with high unmet medical need with a focus on sickle cell disease (SCD) - a painful, inherited blood disorder affecting millions of people around the globe. Sevuparin has the potential to improve the SCD patients' blood flow reducing their pain and the amount of time they will need to spend in hospital. Intravenously administered sevuparin is currently being tested in a phase 2 study which completed enrollment in January 2019 and will report data in mid-2019. In order to broaden sevuparins potential to help SCD patients outside of the hospital setting, Modus Therapeutics in parallel explores subcutaneously administered sevuparin. The first cohort in a

Arcomas CFO lämnar bolaget21.2.2019 23:50:00Pressmeddelande

Arcomas CFO, AnnaPia Johansson har valt att avsluta sin tjänst för nya utmaningar utanför Arcoma. AnnaPia arbetar oförändrat vidare i sin nuvarande tjänst fram till augusti månad eller tills att en ersättare har rekryterats. "Jag vill tacka AnnaPia för hennes ambitiösa arbete för Arcoma och samtidigt önska henne lycka i framtida utmaningar " säger Jesper Söderqvist, VD Arcoma. Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalitet och avancerad teknik. Arcomas produkter erbjuder den senaste digitala bildtekniken kombinerat med tekniskt avancerade rörliga positioneringssystem, vilket tillsammans med ergonomisk skandinavisk design, erbjuder kunden kompletta, konfigurerbara och funktionella digitala röntgensystem. Bolagets produkter säljs via återförsäljare samt via OEM-kunder och det finns idag över 3 500 av Arcomas röntgensystem installerade i hela världen. Arcoma är listat på Nasdaq First North. Certified Advi

Corline Biomedical AB offentliggör bokslutskommuniké för räkenskapsåret 201821.2.2019 08:45:00Pressmeddelande

Corline Biomedical AB ("Corline") publicerar härmed bokslutskommuniké för det fjärde kvartalet och räkenskapsåret 2018. Nedan följer en kort sammanfattning. Fullständig bokslutskommuniké finns tillgänglig på Corlines hemsida (www.corline.se) samt som bifogad fil. VD Henrik Nittmar kommenterar "2018 blev ett genombrottsår för Corline då bolaget gick från preklinisk till klinisk fas i utvecklingen av Renaparin® i och med att RENAPAIR 01-studien öppnade för rekrytering. Nu koncentrerar vi utvecklingsresurserna på att planera inför den värdehöjande fas 2- och fas 3-utvecklingen. Jämfört med branschkollegor har Corline en särskilt gynnsam position i och med att bolaget står på flera ben och parallellt arbetar mot lansering tillsammans med kunder inom medicinteknikområdet. Ett spännande 2019 stundar." Väsentliga händelser under det fjärde kvartalet 2018 Den vetenskapliga tidskriften Transplantation publicerar resultat från den prekliniska utvecklingen av Renaparin®. Här visas i stordjursmode

Arcoma AB: Investerarmöten våren 201915.2.2019 08:46:00Pressmeddelande

15 februari 2019 PRESSRELEASE Arcoma har som ambition att fortsätta öka sitt aktieägarfokus och kontinuerligt förbättra kommunikationen med aktieägare. Under våren 2019 kommer Arcoma medverka på flertalet investerarmöten där aktuella händelser och aktiviteter presenteras. Här ges en ökad inblick i bolagets vision och strategier samt en möjlighet till att ställa frågor till bolagets ledning. SvD Börsplus Temadag "Dubblare" Dag, tid och plats: 5 mars, kl. 13.00, GT 30, Grev Turegatan 30, Stockholm Stockholm Corporate Finance Life Science event Dag, tid och plats: 14 mars, kl. 07.30, Berns, Kammarsalen, Stockholm Redeyes Medtech & Diagnostics event Dag, tid och plats: 14:e maj, Redeye, Mäster Samuelsgatan 42, Stockholm För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soderqvist at arcoma.se Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalite

Corline Biomedical AB: Första patient doserad med Renaparin®15.2.2019 08:42:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man inkluderat första patienten i fas 1-studien RENAPAIR 01. Patienten inkluderades vid transplantationsavdelningen på Uppsala Akademiska sjukhus. Renaparin® är en produkt under utveckling för att förbättra njurtransplantation. I Corlines studie RENAPAIR 01 utvärderas produkten med avseende på tolerabilitet och säkerhet. Studien öppnades för patientrekrytering i slutet av 2018 och första patient är nu doserad och inkluderad i studien. Totalt skall 18 patienter rekryteras och när de 4 första patienterna är utvärderade i Uppsala, öppnas också Karolinska Universitetssjukhuset i Huddinge för rekrytering till studien. Henrik Nittmar, VD i Corline Biomedical AB, kommenterar "Det händer mycket i Corline för tillfället och alla arbetar hårt för att målbilden i bolaget skall uppfyllas. Det gäller såväl vår interna organisation som våra externa samarbetspartners. Därför är det extra roligt när vi når avgörande milstolpar i utvec

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum